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Serum alkaline phosphatase relates 
to cardiovascular risk markers 
in children with high calcium-
phosphorus product
Sílvia Xargay-Torrent1, Núria Espuña-Capote2, Mercè Montesinos-Costa3, Anna Prats-Puig4, 
Gemma Carreras-Badosa1, Ferran Díaz-Roldán1,2, Francis De Zegher5, Lourdes Ibáñez6, 
Judit Bassols1,7 & Abel López-Bermejo1,2
Although alkaline phosphatase (ALP) correlates with cardiovascular risk in adults, there are no studies 
in children. We evaluated the association between serum ALP levels, calcium-phosphorus product 
(Ca*P) and cardiovascular risk markers in healthy children. Children aged 7.9 ± 1.4 (n = 379) were 
recruited in this cross-sectional study. The main outcome measures were systolic and diastolic blood 
pressure (SBP and DBP) and carotid intima-media thickness (cIMT). Additional assessments were 
body-mass index (BMI), waist circumference, homeostatic model assessment of insulin resistance 
(HOMA-IR) and fasting lipids, ALP, serum calcium, phosphorus and Ca*P. ALP was directly correlated 
with BMI (p < 0.0001), waist circumference (p < 0.0001), SBP (p < 0.0001), cIMT (p = 0.005), HOMA-IR 
(p < 0.0001), and fasting triglycerides (p = 0.0001). Among them, in children with Ca*P values above the 
median the associations were BMI (r = 0.231; p = 0.001), waist (r = 0.252; p < 0.0001), SBP (r = 0.324; 
p < 0.0001), cIMT (r = 0.248; p = 0.001) and HOMA-IR (r = 0.291; p < 0.0001)]. ALP independently 
associated with SBP (β = 0.290, p < 0.001) and cIMT (β = 0.179, p = 0.013) in children with higher 
Ca*P, after adjusting for confounding variables. Circulating ALP is associated with a more adverse 
cardiovascular profile in children with higher Ca*P. We suggest that serum ALP and Ca*P levels could 
contribute to the assessment of risk for cardiovascular disease in children.
Cardiovascular disorders have become a major public health concern due to their high prevalence in the adult 
population, thus their prevention during childhood is crucial. Consequently, gaining insight into early processes 
of disease and discovering new biomarkers for early intervention may turn out to be valuable.
Alkaline phosphatase (ALP) is widely expressed, most abundantly in bone, liver and kidneys. Circulating ALP 
originates mostly from bone and liver in adults, and predominantly from bone from birth to adolescence1. ALP 
typically catalyses the removal of the phosphate group from diverse phosphate-containing molecules, among 
other reactions1. Physiologically, one of the main roles of ALP is to help in the mineralization of hard tissues, the 
process whereby hydroxyapatite is deposited in the extracellular matrix, as it supplies the required phosphorus 
pool2.
In adults, positive correlations of ALP with waist circumference, blood pressure and serum triglycerides have 
been described, although these associations have not been adjusted for BMI3. Indeed, obese adults have higher 
concentrations of circulating ALP4. High circulating ALP, however, has been related to cardiovascular and cor-
onary heart disease events independently of body-mass index (BMI), systolic blood pressure (SBP) or serum 
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triglycerides3,5. Additional studies in older adults have also supported that high ALP levels associated with an 
increased risk of 1.19 and 1.10 of coronary heart disease and cardiovascular mortality, respectively, after adjust-
ment for BMI6. In adult patients with kidney disease high levels of serum ALP were also linked to increased 
cardiovascular-related hospitalization7. No studies, however, have been reported in children.
Both calcium and phosphorus are essential substrates involved in the mineralization process. Whereas phys-
iological calcification occurs in hard tissues, the same process can occur pathologically in soft tissues. Serum 
calcium-phosphorus product (Ca*P) has been linked to vascular calcification, and thus been regarded as a risk 
factor for extra-skeletal calcification8. For example, an elevated serum Ca*P concentration is considered to be a 
risk factor for coronary artery disease in adults with metabolic syndrome9.
In this context, our aim is to study whether circulating ALP concentrations are related to cardiovascular risk 
markers in school-aged children, particularly in those with higher Ca*P. As a secondary aim, we study the asso-
ciations of ALP with anthropometric and metabolic parameters as they might act as confounding factors in car-
diovascular risk assessment.
Results
Results for anthropometric, metabolic and cardiovascular parameters are shown in Table 1 for all the studied 
children (n = 379) enrolled in the study, and for subgroups thereof according to the median of Ca*P. None of 
the variables significantly differed among low and high Ca*P subgroups, except for age, HDL cholesterol and, as 
expected, calcium and phosphorus levels (Table 1).
As regards the whole sample of children, serum ALP levels were related to various metabolic and cardio-
vascular parameters. Specifically, in the whole sample of subjects, ALP showed positive correlations with BMI, 
BMI-SDS, waist circumference, SBP, cIMT, insulin, HOMA-IR and fasting triglycerides (Table 2); and to a lesser 
extent, associations were also found with age, fat fraction and DBP (Table 2).
When dividing the sample of children by Ca*P groups, the ALP associations with BMI, BMI-SDS, waist cir-
cumference, insulin, and HOMA-IR were independent of the Ca*P group (Table 2). Serum triglycerides posi-
tively correlated with ALP only in the lower Ca*P group (r = 0.215; p = 0.003). Within the higher Ca*P group, 
circulating ALP levels were specifically associated with age (r = 0.205; p = 0.005), fat mass (r = 0.151; p = 0.037), 
SBP (r = 0.324; p < 0.0001; Fig. 1A) and cIMT (r = 0.248; p = 0.001: Fig. 1B; Table 2).
Next, we investigated whether ALP was preferentially related to SBP and cIMT in children with higher Ca*P 
rather than in the lower Ca*P group. The interaction between ALP and Ca*P was significant after ANCOVA test 
for cIMT (p = 0.037, Table 3), confirming that the correlation between ALP and cIMT was stronger in children 
with higher Ca*P (r = 0.248) than in those with lower Ca*P (r = 0.053; Table 2). For SBP, the ANCOVA test did 
not reach statistical significance (p = 0.050, Table 3).
Finally, in multivariable regression analyses adjusting for confounding variables (age, puberty, gender, BMI, 
HOMA-IR and triglycerides), ALP was shown to be independently associated with SBP (β = 0.290; p < 0.0001, 
R2 = 0.10), and with cIMT (β = 0.179; p < 0.013, R2 = 0.04; Table 4) in high Ca*P children.
All subjects
Ca*P below the 
median
Ca*P above the 
median
n 379 189 190
Gender (female, %) 49.6 47.6 51.6
Age (years) 7.9 ± 1.4 8.1 ± 1.4 7.6 ± 1.5b
Puberty (Tanner >1, %) 13.2 13.2 13.2
BMI (kg/m2) 19.5 ± 4.2 19.6 ± 4.4 19.3 ± 4.0
BMI-SDS (z-score) 0.67 ± 1.45 0.65 ± 1.46 0.70 ± 1.44
Waist (cm) 65 ± 12 65 ± 12 64 ± 12
Fat mass (%) 30.2 ± 9.9 30.7 ± 10.2 29.7 ± 9.4
SBP (mmHg) 106 ± 10 106 ± 11 105 ± 10
DBP (mmHg) 61 ± 8 61 ± 8 61 ± 7
cIMT (mm) 0.041 ± 0.007 0.041 ± 0.007 0.040 ± 0.007
Insulin (mcU/ml) 5.2 ± 4.7 5.4 ± 5.0 5.0 ± 4.4
HOMA-IR 1.1 ± 1.1 1.2 ± 1.2 1.1 ± 1.0
HDL cholesterol (mg/dL) 58 ± 15 56 ± 14 60 ± 15a
Triglycerides (mg/dL) 61 ± 31 63 ± 33 60 ± 29
Alkaline phosphatase (U/L) 240 ± 55 241 ± 58 240 ± 52
Calcium (mg/dL) 9.9 ± 0.3 9.8 ± 0.3 10.0 ± 0.3b
Phosphorus (mg/dL) 4.9 ± 0.4 4.6 ± 0.3 5.2 ± 0.3b
Ca*P 49 ± 5 45 ± 3 52 ± 3b
Table 1. Anthropometric, metabolic and cardiovascular variables in the studied subjects and in subgroups 
according to the median of the calcium and phosphorus product (Ca*P). Data are shown as mean ± SD for 
quantitative variables. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; cIMT, 
carotid intima-media thickness; HOMA-IR, Homeostatic model assessment of insulin resistance; HDL, high-
density lipoprotein; Ca*P, calcium-phosphorus product. ap < 0.05; bp < 0.001 for differences by Student’s t-test.
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Discussion
Circulating ALP was found to relate to cardiovascular risk markers, such as SBP and cIMT, in school-aged chil-
dren with higher circulating Ca*P. Serum ALP and Ca*P concentrations might thus contribute in the assessment 
of cardiovascular risk during childhood.
The present study appears to be the first to have related serum ALP levels to cardiovascular risk factors in 
children. Supporting our data, results reported in adults, showed that high ALP levels correlated with the risk of 
developing cardiovascular disease3,6 and total mortality5,10. Additionally, SBP and cIMT were also shown to be 
positively associated with serum ALP levels in hypertensive men11.
In bone, maturation of osteoblasts is coupled to the release of ALP-containing microvesicles that promote 
mineral deposition. Equivalent structures have been found in vascular tissue12. Metabolic imbalances, such 
as elevated calcium or phosphate levels, stimulate the up-regulation of several osteogenic markers in vascular 
smooth muscle cells, together with the secretion of the calcifying microvesicles13–16. This effect, coupled to down-
regulation of mineralization inhibitors in serum, eventually leads to vascular calcification15. Interestingly, ALP 
hydrolyses a major mineralization inhibitor, the inorganic pyrophosphate, thus regulating the propagation of 
mineralization17–20. Under pathological conditions, the enzyme contributes to the specific calcification of the 
medial layer of vasculature21, which triggers vascular changes as assessed by cIMT22. In a context of mineral 
homeostasis dysregulation in children, such as in renal diseases, higher serum ALP levels have been linked con-
sistently to increased cIMT23,24. Together, these data fit with the present finding that higher ALP concentrations 
relate to greater cIMT in children with higher Ca*P.
Medial vascular calcification is similar to bone mineralization25 and causes concentric calcification of the 
blood vessel and elastinolysis26. This process has substantial cardiovascular consequences, resulting in vascular 
stiffening, reduced compliance and elastance, and ultimately increasing SBP and cardiac workload, and causing 
left ventricular cardiac hypertrophy and heart failure26–31. Thus, it seems plausible that due to early vascular cal-
cification, SBP may be elevated. Accordingly, serum ALP levels have been associated with markers of vascular 
function and blood pressure in adults with and without hypertension11,32.
Ca*P levels seem to be influenced by age in our sample. Children between 7 and 10 years old may be using 
high levels of calcium for bone growth33, however calcium levels are rather stable during childhood34. On the con-
trary, phosphorus levels decrease when infants and children grow old34,35, thus affecting Ca*P levels. Therefore, 
our subsequent results have been adjusted for age to correct for this physiological effect. Our results did not 
reveal Ca*P as a cardiovascular risk factor since both groups of children showed a similar cardiovascular pro-
file. Moreover, the role of Ca*P as a risk factor for cardiovascular diseases has been controversial36. Instead, the 
interaction between the Ca*P and ALP levels would indicate the outcome, thus in the high Ca*P group, ALP 
levels associated positively with cardiovascular risk markers (SBP and cIMT) but not in low Ca*P subgroup. This 
suggests the requirement of both elevated Ca*P and elevated ALP to render a poorer cardiovascular profile. As a 
consequence, when ALP or Ca*P were raised alone, there were no effects on SBP or cIMT. It is thus possible that 
high Ca*P primes children to develop vascular calcification while high ALP levels trigger the process12.
Study limitations include: (i) bone and liver isoforms of ALP were not discriminated, although, as said, most 
ALP derives from bone in children, (ii) the cross-sectional study design, which excluded proof of causality in the 
relationship between circulating ALP and either SBP or cIMT, (iii) relatively weak correlations of these clinical 
associations; however, taken into account that this is a population of healthy children, we believe they are notable 
All subjects (n = 379)
Ca*P below the 
median (n = 189)
Ca*P above the 
median (n = 190)
r p-value r p-value r p-value
Age (years) 0.104 0.042 0.010 0.893 0.205 0.005
BMI (kg/m2) 0.186 <0.001 0.148 0.042 0.231 0.001
BMI-SDS (z-score) 0.176 0.001 0.150 0.039 0.205 0.005
Waist (cm) 0.202 <0.001 0.159 0.028 0.252 <0.001
Fat mass (%) 0.136 0.008 0.123 0.093 0.151 0.037
SBP (mmHg) 0.214 <0.001 0.125 0.086 0.324 <0.001
DBP (mmHg) 0.110 0.032 0.103 0.158 0.119 0.102
cIMT (mm) 0.145 0.005 0.053 0.469 0.248 0.001
Insulin (mcU/ml) 0.210 <0.001 0.156 0.032 0.280 <0.001
HOMA-IR 0.211 <0.001 0.150 0.040 0.291 <0.001
HDL cholesterol (mg/dL) −0.062 0.226 −0.073 0.318 −0.051 0.485
Triglycerides (mg/dL) 0.178 0.001 0.215 0.003 0.129 0.075
Calcium (mg/dL) 0.094 0.067 0.084 0.251 0.125 0.087
Phosphorus (mg/dL) −0.036 0.489 −0.004 0.962 −0.098 0.181
Ca*P 0.000 0.993 0.045 0.535 −0.030 0.679
Table 2. Pearson correlation coefficients for alkaline phosphatase and selected variables in the studied subjects 
and in subgroups according to the median of calcium and phosphorus product (Ca*P). BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; cIMT, carotid intima-media thickness; HOMA-IR, 
Homeostatic model assessment of insulin resistance; HDL, high-density lipoprotein; Ca*P, calcium-phosphorus 
product.
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and expect to find stronger correlations in children at higher risk for cardiovascular disease, such as those with a 
positive family history for this disease.
Whether the associations suggested by our results could be applied to the clinic, as part of a set of biomarkers 
to assess cardiovascular risk at childhood, should be confirmed in appropriate longitudinal studies. Moreover, the 
limitations of using ALP as a biomarker have to be explored as well, since growth spurts/puberty in children may 
result in highly variable ALP.
a
b
Figure 1. Correlation graphs between alkaline phosphatase (ALP) and cardiovascular risk markers in children. 
(A) Relationship between serum ALP and systolic blood pressure (SBP) in subgroups thereof according to the 
Ca*P median (Below the median r = 0.125, p = 0.086; above the median r = 0.324 p < 0.0001). (B) Relationship 
between serum ALP and carotid intima-media thickness (cIMT) in subgroups thereof according to the median 
of the calcium and phosphorus product (Ca*P; below the median r = 0.053, p = 0.469; above the median 
r = 0.248, p = 0.001).
SBP cIMT
F p-value F p-value
Ca*P 4.62 0.032 4.93 0.027
Alkaline phosphatase 19.79 <0.001 9.44 0.002
Ca*P x Alkaline 
phosphatase 3.87 0.050 4.37 0.037
Table 3. ANCOVA analysis testing the interaction of calcium and phosphorus product (Ca*P) in the 
association of alkaline phosphatase and SBP/cIMT (n = 379). SBP, systolic blood pressure; cIMT, carotid intima-
media thickness; Ca*P, calcium-phosphorus product.
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In summary, higher serum ALP levels were found to associate with a more unfavourable cardiovascular profile 
in children with higher Ca*P. Further studies are warranted to confirm whether circulating ALP and Ca*P levels 
might help in the detection of early vascular damage, and contribute to the development of paediatric strategies 
aimed at preventing cardiovascular disease in adulthood.
Methods
Population and ethics. A sample of school-aged children (n = 379), without a family history of cardio-
vascular disease (as assessed by interviewing the parents), participated in the study. Subjects were consecutively 
recruited among those seen in a primary care setting in Northeastern Spain [(mean age of 7.9 ± 1.4 years; mean 
body mass index (BMI)-standard deviation score (SDS) of 0.67 ± 1.45]. Puberty was assessed by a specifically 
trained nurse using Tanner criteria. Prepubertal children were those in Tanner stage I. Exclusion criteria were: 
major congenital anomalies; abnormal blood count; abnormal liver, kidney or thyroid functions; chronic illness 
or prolonged use of medication; acute illness or use of medication during the month previous to the potential 
enrolment. The study protocol was approved by the Institutional Review Board of Dr Josep Trueta Hospital and 
was carried out according with The Code of Ethics of the World Medical Association (Declaration of Helsinki). 
Informed written consent was obtained from the parents. All data generated or analysed during this study are 
included in this published article.
Clinical assessments. Clinical examination was carried out in the morning. A calibrated scale and 
a Harpenden stadiometer were used to obtain weight and height measures, respectively. BMI was calculated 
with the following formula: weight in kg/(height in meters)2. BMI-SDS adjusted for age and sex, was com-
puted using regional normative data37. Waist circumference at the umbilical level was measured in the supine 
position. Body composition was determined by bioelectric impedance (Hydra Bioimpedance Analyzer 4200, 
Xitron Technologies) and fat mass percentage was quantified with the formula: Fat mass = (body weight − lean 
mass)/*100. After a 10-minute rest, blood pressure was taken on the right arm with the child supine, using an 
electronic sphygmomanometer (Dinamap Pro 100, GE Healthcare).
High-resolution ultrasound measurement of carotid intima-media thickness. Carotid 
intima-media thickness (cIMT) was assessed by high-resolution ultrasonography (MyLabTM25, Esaote). Images 
were obtained using a linear 12-MHz transducer on the right side at the level of the distal common carotid artery, 
one centimetre away from its bifurcation. The cIMT value was computed as the average of 5 measurements. 
Intra-subject coefficient of variation was below 6%. None of the children included in the study exhibited visible 
signs of calcification as assessed by ultrasound.
Laboratory variables. Blood sampling was carried out in the morning under fasting conditions. Serum 
glucose was quantified by the hexokinase method. Insulin was detected by immunochemiluminiscence (Immulite 
2000, Diagnostic Products). The limit of detection was 0.4 mIU/L and coefficient of variation (CV) was less than 
β p-value R2
SBP as dependent variable
All children (n = 379) <0.001 0.14
    BMI 0.317 <0.001 0.12
    Alkaline phosphatase 0.156 0.002 0.02
Ca*P below the median (n = 189) <0.001 0.21
    BMI 0.396 <0.001 0.20
    Triglycerides 0.142 0.046 0.01
Ca*P above the median (n = 190) <0.001 0.12
    Alkaline phosphatase 0.295 <0.001 0.10
    Age 0.156 0.028 0.02
cIMT as dependent variable
All children (n = 379) <0.001 0.06
    BMI 0.217 <0.001 0.05
    Alkaline phosphatase 0.110 0.032 0.01
Ca*P below the median (n = 189) <0.001 0.08
    BMI 0.228 0.001 0.05
    Female gender 0.199 0.005 0.03
Ca*P above the median (n = 190) <0.001 0.11
    Age 0.166 0.026 0.06
    Alkaline phosphatase 0.180 0.014 0.04
    BMI 0.150 0.046 0.01
Table 4. Multivariable regression analysis of SBP and cIMT as dependent variables in the studied subjects 
and in subgroups thereof according to the median of calcium and phosphorus product (Ca*P). Variables 
included in the model were the following: age, puberty, gender, BMI, SBP, HOMA-IR, triglycerides and alkaline 
phosphatase.
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10%. Homeostatic model assessment of insulin resistance (HOMA-IR) index was calculated according to the 
formula: fasting insulin (µU/mL) × fasting glucose (mg/dL)/405. Total triglycerides (TG) were quantified with 
glycerolphosphate oxidase (ARCHITECT, Abbott Laboratories), with detection threshold of 5 mg/dL and CV 
below 5%. A homogeneous method of selective detergent with accelerator (ARCHITECT, Abbott Laboratories) 
was used to determine HDL-cholesterol levels, with detection limit and CV of 2.5 mg/dL and inferior to 4%, 
respectively. ALP was quantified by colorimetrical detection of p-nitrophenyl phosphate product, with a limit of 
detection of 5 U/L. Inorganic phosphorus was colorimetrically assayed after reacting with ammonium molybdate 
in acidic medium (detection limit 0.3 mg/dL). Calcium was assessed using the chromophore 5-nitro-5′-methyl-
1,2-bis(o-aminophenoxy)ethan-N,N,N’,N’-tetraacetic acid. Ca*P was calculated as the product between serum 
calcium and phosphorus.
Statistics. Statistical analyses were performed using SPSS version 22.0 (SPSS Inc.). The study has an 
80% power to detect a significant Pearson correlation coefficient of at least 0.15 between ALP levels and 
cardio-metabolic parameters, accepting an alpha risk of 0.05 in a bilateral contrast (GRANMO, IMIM, ver-
sion 7.12). Results are expressed as mean ± standard deviation (SD). Median Ca*P value was used to categorize 
subjects in subgroups with serum Ca*P above versus below the median. Non-normally distributed variables 
(Kolmogorov-Smirnov normality test) were mathematically transformed to improve symmetry with logarithmic 
and quadratic functions. Differences between Ca*P subgroups were assessed by Student t-test (continuous data) 
and by Chi square (categorical data). The relation between variables was tested by Pearson bivariate correlations 
followed by multivariable linear regression analyses. The stepwise method was used for computing the inde-
pendent variables. Ca*P interaction in the association between ALP and systolic blood pressure (SBP)/cIMT was 
assessed by analysis of covariance (ANCOVA). Significance level was set at p < 0.05.
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